Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Bay Colony Advisory Group Inc d b a Bay Colony Advisors

Bay Colony Advisory Group Inc d b a Bay Colony Advisors lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 32.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,072 shares of the medical instruments supplier’s stock after selling 989 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Becton, Dickinson and Company were worth $470,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of BDX. Tompkins Financial Corp boosted its holdings in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the last quarter. Wesbanco Bank Inc. boosted its holdings in shares of Becton, Dickinson and Company by 1.9% in the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock valued at $580,000 after purchasing an additional 48 shares during the last quarter. S.A. Mason LLC boosted its holdings in shares of Becton, Dickinson and Company by 3.7% in the 4th quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock valued at $321,000 after purchasing an additional 50 shares during the last quarter. Americana Partners LLC boosted its holdings in shares of Becton, Dickinson and Company by 3.5% in the 4th quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier’s stock valued at $345,000 after purchasing an additional 52 shares during the last quarter. Finally, Novare Capital Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 5.2% in the 4th quarter. Novare Capital Management LLC now owns 1,110 shares of the medical instruments supplier’s stock valued at $252,000 after purchasing an additional 55 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX opened at $229.51 on Friday. The company has a 50-day moving average of $232.98 and a 200-day moving average of $232.73. The company has a market capitalization of $65.90 billion, a P/E ratio of 38.12, a PEG ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 1.81%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 69.10%.

Becton, Dickinson and Company declared that its board has initiated a share repurchase plan on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Piper Sandler raised their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, Barclays raised their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $278.29.

Insider Activity

In other news, Director Bertram L. Scott sold 700 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total value of $159,593.00. Following the completion of the transaction, the director now directly owns 36,033 shares of the company’s stock, valued at approximately $8,215,163.67. The trade was a 1.91 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Roland Goette sold 638 shares of Becton, Dickinson and Company stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the transaction, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at $3,113,949.51. This trade represents a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 6,061 shares of company stock valued at $1,379,521. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.